Submit orforglipron for obesity to global regulatory authorities
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Oct 2025
- Due
- 31 Dec 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity”
What we found
Evidence strength A What the grades mean
The February 2026 8-K, covering Q4 2025, reports submissions of orforglipron for obesity to regulators in the U.S., Japan and the EU, indicating submission within 2025.
-
A ELI Lilly & Co 8-K filed 2026-02-04
“submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU.” ✓ confirmed on the page
-
A ELI Lilly & Co 8-K filed 2026-02-04
“and submitting orforglipron for approval.” ✓ confirmed on the page
Market reaction: the shares moved +5.3% against the S&P 500 over the three sessions around the disclosure (3 Feb 2026 to 6 Feb 2026). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Global regulatory submissions for orforglipron in obesity
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-LLY-006027 · Corrections policy